FutureWiseResearch: Global Market Research Reports, USA, UK

Overview

Human Microbiome Therapeutics Market Overview:

According to FutureWise analysis the market for human microbiome therapeutics in 2023 is US$ 0.63 billion, and is expected to reach US$ 3.5 billion by 2031 at a CAGR of 23.92%.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Human Microbiome Therapeutics Market trend that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Human Microbiome Therapeutics Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Human Microbiome Therapeutics Market:

Bristol-Myers Squibb Co.
Dow Inc.
ENTEROME SA
Ferring Pharmaceuticals AS
Johnson and Johnson
Kaleido Biosciences Inc.
PureTech Health Plc
Second Genome Therapeutics
Seres Therapeutics Inc.
Takeda Pharmaceutical Co. Ltd.
Vedanta Biosciences
Whole Biome
Naked Biome
Evelo Biosciences
LNC Therapeutics
Biotagenics
Oxidien Pharmaceuticals, LLC
BoobyBiome
4D Pharma PLC
UBiome
Carbiotix
E.I. du Pont de Nemours and Company
Finch Therapeutics
GNUbiotics Sciences
ClearB Therapeutics
GoodBelly
GoodGut
Synlogic
16S Technologies
5QBD-Biotech

(Note: The list of the major players will be updated with the latest market scenario and trends)

Human Microbiome Therapeutics Market Segmentation:

By Product Type

Probiotics
Prebiotics
Medical Foods
Prescription Drugs

By Therapeutic Area

Autoimmune Disorders
Dental Disorders
Digestive and Gastrointestinal Disorders
Dermatological Disorders
Infectious Disease
Metabolic Disorders
Oncology
Others

By Indication

Acne Vulgaris
Atopic Dermatitis
Clostridium difficile Infection
Colorectal Cancer
Diabetes
Inflammatory Bowel Disease (IBD)
Lactose Intolerance
Lung Cancer
Non-alcoholic steatohepatitis (NASH)
Obesity
Coeliac Disease

By Approach

Small Molecule Therapies
Single Strain Whole Bacteria
Microbial Consortia
Genetically Modified Single Strain Bacteria
Phage Cocktail
Microbial Ecosystems

By Region

North America
Europe
Asia-Pacific
Latin America
Middle East and Africa

Competitive Landscape:

Tier 1 players- established companies in the market with a major market share
Tier 2 players
Emerging players which are growing rapidly
New Entrants

FutureWise Key Takeaways:

Growth prospects
SWOT analysis
Key trends
Key data-points affecting market growth

Objectives of the Study:

To provide with an exhaustive analysis on the Human Microbiome Therapeutics Market By Product Type, By Therapeutic Area, By Indication, By Approach and By Region.
To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
To evaluate and forecast micro-markets and the overall market
To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:

We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
The customisation offered are free of charge with purchase of any license of the report
You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

1. Market Introduction
- 1. Objectives of the Study
  2. Market Definition
  3. Market Scope
  3.1 . Years Considered for the Study
  3.2 . Market Covered
  4. Currency
  5. Limitations
  6. Stakeholders
2. Research Methodology
- 1. Research Data
  1.1 . Secondary Data
  1.1.1 . Key Data from Secondary Sources
  1.2 . Primary Data
  1.2.1. Key Data from Primary Sources
  2. Market Size Estimation
  3. Market Breakdown and Data Triangulation
  4. Assumptions for the Study
3. Executive Summary
- 1. Market Outlook
  2. Segment Outlook
  3. Competitive Insights
4. Global Human Microbiome Therapeutics Market Variables, Trends and Scope
- 1. Market Lineage Outlook
  2. Penetration and Growth Prospect Mapping
  3. Industry Value Chain Analysis
  4. Cost Analysis Breakdown
  5. Product Overview
  6. Regulatory Framework
  6.1. Reimbursement Framework
  6.2. Standards and Compliances
5. Market Overview
- 1. Market Dynamics
  1.1. Market Driver Analysis
  1.1.1. Increasing focus of Companies on Brand Protection
  1.1.2. Untapped Opportunities in Emerging Regions
  1.2. Market Restraint Analysis
  1.2.1. High Cost Associated with Implementation of Predictive Analysis
  1.3. Industry Challenges
  1.3.1. Presence of Ambiguous Regulatory Framework
6. Global Human Microbiome Therapeutics Market Analysis Tools
- 1. Industry Analysis - Porter’s
  1.1. Supplier Power
  1.2. Buyer Power
  1.3. Substitution Threat
  1.4. Threat from New Entrants
  1.5. Competitive Rivalry
  2. Pestel Analysis
  2.1. Political Landscape
  2.2. Environmental Landscape
  2.3. Social Landscape
  2.4. Product Landscape
  2.5. Legal Landscape
  3. Major Deals And Strategic Alliances Analysis
  3.1. Joint Ventures
  3.2. Mergers and Acquisitions
  3.3. Licensing and Partnership
  3.4. Product Collaborations
  3.5. Strategic Divestments
  4. Market Entry Strategies
  5. Case Studies
7. Global Human Microbiome Therapeutics Market, By Product Type Historical Analysis and Forecast 2023-2031 (USD Million)
- 1. Probiotics
  2. Prebiotics
  3. Medical Foods
  4. Prescription Drugs
8. Global Human Microbiome Therapeutics Market, By Therapeutic Area Historical Analysis and Forecast 2023-2031 (USD Million)
- 1. Dental Disorders
  2. Autoimmune Disorders
  3. Digestive and Gastrointestinal Disorders
  4. Dermatological Disorders
  5. Infectious Disease
  6. Metabolic Disorders
  7. Oncology
  8. Others
9. Global Human Microbiome Therapeutics Market, By Indication Historical Analysis and Forecast 2023-2031 (USD Million)
- 1. Acne Vulgaris
  2. Atopic Dermatitis
  3. Clostridium difficile Infection
  4. Colorectal Cancer
  5. Diabetes
  6. Inflammatory Bowel Disease (IBD)
  7. Lactose Intolerance
  8. Lung Cancer
  9. Non-alcoholic steatohepatitis (NASH)
  10. Obesity
  11. Coeliac Disease
10. Global Human Microbiome Therapeutics Market, By Approach Historical Analysis and Forecast 2023-2031 (USD Million)
- 1. Small Molecule Therapies
  2. Single Strain Whole Bacteria
  3. Microbial Consortia
  4. Genetically Modified Single Strain Bacteria
  5. Phage Cocktail
  6. Microbial Ecosystems
11. North America Human Microbiome Therapeutics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
  2.1. U.S.A
  2.2. Canada
  2.3. Mexico
  3. Market Size (USD Million) Forecast for North America 2023-2031
12. Latin America Human Microbiome Therapeutics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
  2.1. Brazil
  2.2. Venezuela
  2.3. Argentina
  2.4. Rest of Latin America
  3. Market Size (USD Million) Forecast for Latin America 2023-2031
13. Europe Human Microbiome Therapeutics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
  2.1. Germany
  2.2. U.K
  2.3. France
  2.4. Italy
  2.5. Spain
  2.6. Russia
  2.7. Poland
  2.8. Rest of Europe
  3. Market Size (USD Million) Forecast for Europe 2023-2031
14. Asia Pacific Human Microbiome Therapeutics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
  2.1. Japan
  2.2. China
  2.3. India
  2.4. Australia and New Zealand
  2.5. ASEAN
  2.6. Rest of Asia Pacific
  3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031
15. Middle East and Africa Human Microbiome Therapeutics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
  2.1. GCC
  2.2. Israel
  2.3. South Africa
  2.4. Rest of MEA
  3. Market Size (USD Million) Forecast for MEA 2023-2031
16. Market Share Analysis and Competitive Landscape
- 1. Global Landscape - Key Players, Revenue and Presence
  2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
  3. Global Emerging Companies
  4. North America - Market Share Analysis and Key Regional Players
  5. Europe - Market Share Analysis and Key Regional Players
  6. Asia Pacific - Market Share Analysis and Key Regional Players
  7. Global Key Player - Growth Matrix
17. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
- 1. Bristol-Myers Squibb Co.
  1.1. Company Overview
  1.2. Product Portfolio
  1.3. SWOT Analysis
  1.4. Financial Overview
  1.5. Strategic Overview
  2. Dow Inc.
  2.1. Company Overview
  2.2. Product Portfolio
  2.3. SWOT Analysis
  2.4. Financial Overview
  2.5. Strategic Overview
  3. ENTEROME SA
  3.1. Company Overview
  3.2. Product Portfolio
  3.3. SWOT Analysis
  3.4. Financial Overview
  3.5. Strategic Overview
  4. Ferring Pharmaceuticals AS
  4.1. Company Overview
  4.2. Product Portfolio
  4.3. SWOT Analysis
  4.4. Financial Overview
  4.5. Strategic Overview
  5. Johnson and Johnson
  5.1. Company Overview
  5.2. Product Portfolio
  5.3. SWOT Analysis
  5.4. Financial Overview
  5.5. Strategic Overview
  6. Kaleido Biosciences Inc.
  6.1. Company Overview
  6.2. Product Portfolio
  6.3. SWOT Analysis
  6.4. Financial Overview
  6.5. Strategic Overview
  7. PureTech Health Plc
  7.1. Company Overview
  7.2. Product Portfolio
  7.3. SWOT Analysis
  7.4. Financial Overview
  7.5. Strategic Overview
  8. Second Genome Therapeutics
  8.1. Company Overview
  8.2. Product Portfolio
  8.3. SWOT Analysis
  8.4. Financial Overview
  8.5. Strategic Overview
  9. Seres Therapeutics Inc.
  9.1. Company Overview
  9.2. Product Portfolio
  9.3. SWOT Analysis
  9.4. Financial Overview
  9.5. Strategic Overview
  10. Takeda Pharmaceutical Co. Ltd.
  10.1. Company Overview
  10.2. Product Portfolio
  10.3. SWOT Analysis
  10.4. Financial Overview
  10.5. Strategic Overview
  11. Vedanta Biosciences
  11.1. Company Overview
  11.2. Product Portfolio
  11.3. SWOT Analysis
  11.4. Financial Overview
  11.5. Strategic Overview
  12. Whole Biome
  12.1. Company Overview
  12.2. Product Portfolio
  12.3. SWOT Analysis
  12.4. Financial Overview
  12.5. Strategic Overview
  13. Naked Biome
  13.1. Company Overview
  13.2. Product Portfolio
  13.3. SWOT Analysis
  13.4. Financial Overview
  13.5. Strategic Overview
  14. Evelo Biosciences
  14.1. Company Overview
  14.2. Product Portfolio
  14.3. SWOT Analysis
  14.4. Financial Overview
  14.5. Strategic Overview
  15. LNC Therapeutics
  15.1. Company Overview
  15.2. Product Portfolio
  15.3. SWOT Analysis
  15.4. Financial Overview
  15.5. Strategic Overview
  16. Biotagenics
  16.1. Company Overview
  16.2. Product Portfolio
  16.3. SWOT Analysis
  16.4. Financial Overview
  16.5. Strategic Overview
  17. Oxidien Pharmaceuticals, LLC
  17.1. Company Overview
  17.2. Product Portfolio
  17.3. SWOT Analysis
  17.4. Financial Overview
  17.5. Strategic Overview
  18. BoobyBiome
  18.1. Company Overview
  18.2. Product Portfolio
  18.3. SWOT Analysis
  18.4. Financial Overview
  18.5. Strategic Overview
  19. 4D Pharma PLC
  19.1. Company Overview
  19.2. Product Portfolio
  19.3. SWOT Analysis
  19.4. Financial Overview
  19.5. Strategic Overview
  20. UBiome
  20.1. Company Overview
  20.2. Product Portfolio
  20.3. SWOT Analysis
  20.4. Financial Overview
  20.5. Strategic Overview
  21. Carbiotix
  21.1. Company Overview
  21.2. Product Portfolio
  21.3. SWOT Analysis
  21.4. Financial Overview
  21.5. Strategic Overview
  22. E.I. du Pont de Nemours and Company
  22.1. Company Overview
  22.2. Product Portfolio
  22.3. SWOT Analysis
  22.4. Financial Overview
  22.5. Strategic Overview
  23. Finch Therapeutics
  23.1. Company Overview
  23.2. Product Portfolio
  23.3. SWOT Analysis
  23.4. Financial Overview
  23.5. Strategic Overview
  24. GNUbiotics Science
  24.1. Company Overview
  24.2. Product Portfolio
  24.3. SWOT Analysis
  24.4. Financial Overview
  24.5. Strategic Overview
  25. ClearB Therapeutics
  25.1. Company Overview
  25.2. Product Portfolio
  25.3. SWOT Analysis
  25.4. Financial Overview
  25.5. Strategic Overview
  26. GoodBelly
  26.1. Company Overview
  26.2. Product Portfolio
  26.3. SWOT Analysis
  26.4. Financial Overview
  26.5. Strategic Overview
  27. GoodGut
  27.1. Company Overview
  27.2. Product Portfolio
  27.3. SWOT Analysis
  27.4. Financial Overview
  27.5. Strategic Overview
  28. Synlogic
  28.1. Company Overview
  28.2. Product Portfolio
  28.3. SWOT Analysis
  28.4. Financial Overview
  28.5. Strategic Overview
  29. 16S Technologies
  29.1. Company Overview
  29.2. Product Portfolio
  29.3. SWOT Analysis
  29.4. Financial Overview
  29.5. Strategic Overview
  30. 5QBD-Biotech
  30.1. Company Overview
  30.2. Product Portfolio
  30.3. SWOT Analysis
  30.4. Financial Overview
  30.5. Strategic Overview
18. Pre and Post COVID-19 Impact
- 1. Positive influence on the healthcare industry
  2. The financial disruption of the manufacturing sector
  3. Impact of COVID-19 on emerging companies
  4. Significant mandates in the healthcare regulations initiated by administrations
  5. The overall economic slowdown of the developing and developed nations
19. FutureWise SME Key Takeaway Points for Client

Data Pack license: Data Pack license: $1250

Single user license: Single user license: $2850

Multi user license: Multi user license: $3850

Corporate license: Corporate license: $5000

Ask for Discount

Buy Now

Customize This Report

Partner

Report Overview

Table of Contents

List of Tables

List of figures

Overview

Table of Contents

Report Overview

Table of Contents

List of Tables

List of figures

Need Assistance

What you get

What's included

Our Clients